Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant Mycobacterium tuberculosis in China [PDF]
Frontiers in Medicine, 2022 ObjectiveTo investigate the in vitro activities of five oxazolidinones in parallel against the reference strains of different mycobacterial species and clinical isolates of Mycobacterium tuberculosis (Mtb), and shed light on the differences in the ...
Chenqian Wang +10 more
doaj +2 more sources
Assessment of Lipophilicity Parameters of Antimicrobial and Immunosuppressive Compounds [PDF]
Molecules, 2023 Lipophilicity in addition to the solubility, acid-base character and stability is one of the most important physicochemical parameters of a compound required to assess the ADMET properties (absorption, distribution, metabolism, excretion and toxicity) of
Dawid Wardecki +2 more
doaj +2 more sources
New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon? [PDF]
PharmaceuticsMultidrug-resistant tuberculosis (MDR-TB) is a global health concern. Standard treatment involves the use of linezolid, a repurposed oxazolidinone. It is associated with severe adverse effects, including myelosuppression and mitochondrial toxicity.
Ricky Hao Chen +4 more
doaj +2 more sources
In vitro Antimicrobial Activity Comparison of Linezolid, Tedizolid, Sutezolid and Delpazolid Against Slowly Growing Mycobacteria Isolated in Beijing, China [PDF]
Infection and Drug Resistance, 2021 Xia Yu,* Fengmin Huo,* Fen Wang,* Shu’an Wen, Guanglu Jiang, Yi Xue, Lingling Dong, Liping Zhao, Rui Zhu, Hairong Huang National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing ...
Yu X +9 more
doaj +2 more sources
Genomic-based genotype and drug susceptibility profile of Mycobacterium kansasii in China [PDF]
Frontiers in MicrobiologyTo analyze subtypes, microbiological characteristics and antimicrobial susceptibility of Mycobacterium kansasii in China, a total of 153 M. kansasii isolates, collected from national drug resistance surveillance, were genotyped with whole genome ...
Yiting Wang +11 more
doaj +2 more sources
Targeting the Heart of Mycobacterium: Advances in Anti-Tubercular Agents Disrupting Cell Wall Biosynthesis [PDF]
PharmaceuticalsMycobacterium tuberculosis infections continue to pose a significant global health challenge, particularly due to the rise of multidrug-resistant strains, random mycobacterial mutations, and the complications associated with short-term antibiotic ...
Ahmad Diab +2 more
doaj +2 more sources
ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis [PDF]
TrialsBackground The standard of care (SOC) treatment for drug-susceptible pulmonary tuberculosis (DS-TB) consists of isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE).
Linda J. Harrison +26 more
doaj +2 more sources
Assessment of tuberculosis drug efficacy using preclinical animal models and in vitro predictive techniques [PDF]
npj Antimicrobials and ResistanceTuberculosis (TB) killed approximately 1.3 million people in 2022 and remains a leading cause of death from the bacteria Mycobacterium tuberculosis (M.tb); this number of deaths was surpassed only by COVID-19, caused by the SARS-CoV-2 virus. The alarming
Hazem F. M. Abdelaal +16 more
doaj +2 more sources
Comparative In Vitro Drug Susceptibility Study of Five Oxazolidinones Against Mycobacterium tuberculosis in Hainan, China [PDF]
PathogensOxazolidinones, novel synthetic antibacterials, inhibit protein biosynthesis and show potent activity against Gram-positive bacteria, including Mycobacterium tuberculosis (MTB).
Jinhui Dong +9 more
doaj +2 more sources
Neuromyelitis optica causing vision loss during TB treatment with sutezolid: evidence of aberrant immunity following infection [PDF]
IJTLD OpenN.A. Glover +13 more
doaj +2 more sources